This article has been updated from a previous version to include a stock quote.
NEW YORK (GenomeWeb News) - Affymetrix today lowered its full-year revenue forecast for the second time this year as it reported a 1.5 percent dip in second-quarter revenues to $86.9 million from $88.3 million in the comparable period of 2007.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.